In 2016, QIL, Quasar’s Israeli sister company, expend its offices and laboratory. This expansion is in line with Quasar’s growth and advancement within the medical market.
The new laboratory includes larger space and equipment used to support Quasar’s customers.
With the expended laboratory and engineering department Quasar will be able to support the growing needs from its customers.
As rumors of Covid-19 spread in January 2020, and fear gripped most of China, the management had to face facts and realize that a serious crisis was in the offing. Instead of being paralyzed by fear and uncertainty, Quasar’s leadership headed by Ayal Amitai, CEO, began looking ahead, considering courses of action to get the plant working again.
Many supply-chain vulnerabilities stem from long lead times and high levels of cyclicity that prevent the maintenance of the right inventory balance. OEM companies must identify and solve supply-chain vulnerabilities and risk exposures by creating effective mitigation and business-continuity plans.
Today’s advancements in automation systems are evolving at a fast pace. All while becoming more cost-effective to install and maintain.
China’s overall economic recovery in part has been attributed to the strong rebound in the manufacturing sector. The medical devices manufacturing sector specifically recorded an astounding 46.4% growth.
The benefits of transferring production to an experienced contract manufacturer with a track record for performance is the plethora of ideas and innovation that adds more value to the design of the end product.
It takes veteran manufacturers who are specialized in the field of interventional cardiology equipment, to be able to smoothly navigate through this ever-evolving market.
